Atlas market file · Equity · United States
Liquidia CorpLQDA
- Last close
- 89.12
- Change
- +0.84%
- 96-bar range
- 34.21 – 91.36
- As of
- 5 Aug 2026
Liquidia Corp is a pharmaceutical preparations issuer listed as LQDA on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
LQDA
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+793.88% over the window).
Source rail: Yahoo Finance chart API (LQDA). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for LQDA. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
Atlas Pro artifact
LQDA Market Snapshot PDF
The latest snapshot audit passed. Atlas checks entitlement and evidence again when the PDF is requested.
Atlas Pro entitlement required. The release gate runs again when you request the file.
LQDA public profile
Pharmaceutical preparations issuer. Liquidia Corp is connected to current market context, cited company sources and its retained research file.
Liquidia Corp trades as LQDA on NASDAQ. Liquidia Corp (LQDA) has a latest verified close of 89.12, up 0.84%, dated 5 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files LQDA under USA Stocks for browsing.
What changed for Liquidia Corp today
LQDA’s Q1 2026 numbers paint a paradox: $132.9M in revenue and $52.9M in net income sit alongside cautious language about its ability to sustain YUTREPIA sales, the drug meant to anchor its future. The company’s 10-Q filing acknowledges that anticipated cash flows from the product remain speculative, despite the polished press release issued June 8, 2026.
Liquidia operates in the biopharmaceutical space, focusing on pulmonary treatments. Its financials show $401.5M in total assets and $222.8M in cash, but the $4.6M inventory increase to $28.5M raises eyebrows. The company spent $12.6M on R&D, reflecting bets on future pipelines like L606, though filings admit resource allocation for such projects may be overstated.
Key risks include overreliance on YUTREPIA’s uncertain commercial success, inventory buildup without proven demand, and R&D spending efficiency. Catalysts include actual YUTREPIA sales data, FDA decisions on L606, and inventory turnover improvements. The stock’s diluted EPS of $0.52 and 101.1M shares outstanding suggest current profitability, but the real test lies in converting anticipation into recurring revenue.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
LQDA technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on LQDA
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep LQDA research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
LQDA FAQ
What is Liquidia Corp (LQDA)?Liquidia Corp (LQDA) has a latest verified close of 89.12, up 0.84%, dated 5 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Liquidia Corp (LQDA) has a latest verified close of 89.12, up 0.84%, dated 5 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for LQDA?Liquidia Corp (LQDA) has a latest verified close of 89.12, up 0.84%, dated 5 Aug 2026. It brings the latest available chart, company context, cited sources, risks and...
Liquidia Corp (LQDA) has a latest verified close of 89.12, up 0.84%, dated 5 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files LQDA under USA Stocks for browsing.
How often is the LQDA page updated?The LQDA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The LQDA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for LQDA?The LQDA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:LQDA. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The LQDA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:LQDA. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on LQDA?Yes. The workstation can open LQDA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open LQDA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this LQDA page investment advice?No. The LQDA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The LQDA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-07-29. Browse FreedomCore Atlas research notes →